Top Fluconazole Brands You Can Trust Today

Fluconazole, a popular antifungal medication, is widely used to treat various fungal infections, and several pharmaceutical brands have established a reputation for producing high-quality options. Well-known global brands like Pfizer and Novartis have consistently been recognized for their reliability and effectiveness in the production of fluconazole. Additionally, generic drug manufacturers that adhere to rigorous quality standards also offer competitive options, making the medication accessible to a broader audience. To explore a more comprehensive list of the best fluconazole brands and their specific offerings, read on.

Illustration of fluconazole

Best brands of fluconazole in 2025

Diflucan

Diflucan, a brand of fluconazole, is a leading player in the global antifungal market, known for its broad spectrum of activity and effectiveness in treating various fungal infections. The azole class, to which fluconazole belongs, dominated the anti-fungal treatment market with about 50% of the revenue share in 2023. North America, where Diflucan is widely used, holds approximately 41% of the market share due to advanced healthcare infrastructure and high awareness of fungal infections. The increasing incidence of nosocomial infections and fungal diseases, such as those reported by the CDC with over 75,000 hospitalizations in the U.S. in 2017, has fueled the demand for fluconazole products. Major pharmaceutical companies like Pfizer, the manufacturer of Diflucan, continue to invest in research and development to expand the clinical applications of fluconazole. For more detailed information about Diflucan, visit the Pfizer product page.

Flucomet

Fluconazole, commonly marketed under brands like Diflucan, is a highly effective antifungal medication. While "Flucomet" is not a widely recognized brand, major players like Pfizer, Glenmark Pharmaceuticals, and Teva Pharmaceuticals are prominent producers of fluconazole. These companies have significantly contributed to the market, with North America expected to account for a major share due to the high prevalence of fungal infections and nosocomial infections. For instance, in 2017, there were over 75,000 hospitalizations and nearly 9 million outpatient visits for fungal diseases in the U.S. The global fluconazole market is anticipated to grow, driven by an increase in the incidence of fungal infections and strategic investments by key players, such as ANI Pharmaceuticals' acquisition in 2020. More detailed information on fluconazole is available on the FDA website.

Trican

Triflucan, often marketed under the brand name Diflucan by Pfizer, is a highly effective triazole antifungal agent, particularly renowned for its efficacy in treating oropharyngeal candidiasis and cryptococcal meningitis, especially in AIDS patients. The drug has shown significant potency, with in vitro minimum inhibitory concentrations (MIC values) of 8 ug/mL or less against most strains of relevant microorganisms. Since its introduction, fluconazole has demonstrated a high resistance rate in certain Candida species, such as C. tropicalis, with resistance rates increasing to 29.5% in candiduria isolates by 2012-2013. Fluconazole is available in various strengths, including 200mg, 150mg, and 50mg tablets and oral suspensions, and is administered orally or intravenously. For more information about the chemistry and chemical properties of Triflucan, visit the PharmaCompass page on Triflucan.

Flucozol

Fluconazole, often branded as Diflucan, is a highly effective antifungal medication, with Fluconazole exhibiting minimum inhibitory concentrations (MIC values) of 8 ug/mL or less against most (>=90%) strains of several microorganisms. It is cleared primarily by renal excretion, with approximately 80% of the administered dose appearing in the urine as unchanged drug. In pharmacokinetic studies, fluconazole has shown significant interactions with other drugs, such as an 88% increase in phenytoin AUC and a 21% increase in theophylline AUC when co-administered. The drug's half-life in adults is approximately 33.4 hours, which can vary based on age and renal function. Fluconazole's efficacy is highlighted by its ability to eradicate the infecting organism in 76% of treated patients compared to 11% for nystatin-treated patients. For detailed information, consult the official FDA documentation.

Forcan

Fluconazole, often marketed under the brand name Diflucan by Pfizer, is a highly effective antifungal medication, with bioavailability exceeding 90% when taken orally. It is widely used for treating various fungal infections, including candidemia and systemic candidiasis, and its elimination half-life ranges from 20 to 50 hours. In 2022, fluconazole was the 160th most commonly prescribed medication in the United States, with over 3 million prescriptions. The drug is primarily excreted through the kidneys, with approximately 61-88% of the dose appearing in the urine as unchanged drug. Its broad-spectrum activity and favorable safety profile make it a leading choice in the antifungal drugs market. For comprehensive details, refer to the FDA documentation.

Flucostat

Flucostat, a brand of fluconazole, is renowned for its high efficacy in treating various fungal infections, including those caused by Candida albicans and Cryptococcus neoformans. With a bioavailability of over 90% when administered orally, Flucostat ensures effective treatment with minimal dosage adjustments. The drug's long plasma elimination half-life of approximately 30 hours supports single-dose or once-daily dosing regimens. In clinical studies, Flucostat has demonstrated no significant effects on steroid levels, even at doses of 200-400 mg, and has shown a low incidence of resistance in treated organisms. Its pharmacokinetics are well-established, with about 80% of the administered dose excreted unchanged in the urine. For more detailed information, you can consult the official Flucostat prescribing information.

Flucoral

Fluconazole, often marketed under brands like Diflucan, is a highly effective antifungal medication, with Fluconazole from reputable manufacturers being a top choice for treating various fungal infections. It exhibits strong efficacy, with 76% of fluconazole-treated patients showing eradication of the infecting organism, compared to 11% for nystatin-treated patients. The drug is primarily cleared by renal excretion, with approximately 80% of the administered dose appearing in the urine as unchanged drug. Its long plasma elimination half-life of around 30 hours supports single-dose and once-daily dosing regimens. Fluconazole is also known for its selective inhibition of fungal cytochrome P450 dependent enzymes, making it a targeted and effective treatment.

Diflazon

Diflucan, produced by Pfizer, is a leading brand for fluconazole, a synthetic triazole antifungal agent renowned for its high bioavailability of over 90% when administered orally compared to intravenous administration. It is available in various strengths, including 50 mg, 100 mg, 150 mg, and 200 mg tablets, and as an oral suspension. The drug exhibits dose-proportional pharmacokinetics, with peak plasma concentrations occurring between 1 and 2 hours and a terminal plasma elimination half-life of approximately 30 hours. Diflucan can be taken without regard to meals, as food does not affect its exposure. Its pharmacokinetics are significantly influenced by renal function, necessitating dose adjustments in patients with impaired renal function. For more detailed information, explore the clinical pharmacology of Diflucan.

Triflucan

Diflucan, a brand of fluconazole produced by Pfizer, is renowned for its efficacy in treating various fungal infections. It is particularly notable for its use in treating cryptococcosis, with the global cryptococcosis market anticipating growth to $7.0 billion by 2027, driven in part by the effectiveness of fluconazole. The drug has a significant impact on pharmacokinetics, with studies showing it can increase the AUC and Cmax of other medications like theophylline by 21% and 13%, respectively. Diflucan's half-life varies by age, from 73.6 hours in premature newborns to 33.4 hours in adults, highlighting its adaptability across different patient groups. Its widespread use is also reflected in the anti-fungal treatment market, which is expected to grow at a CAGR of 3.88% from 2024 to 2032, with azoles like fluconazole dominating about 50% of the market share. For detailed information on Diflucan, visit the FDA's official labeling page.

Fluval

Fluconazole, a widely used antifungal medication, is not associated with the brand name "Fluval," which is actually a brand known for aquarium products. However, key players in the fluconazole market include Pfizer, Bayer, Teva Pharmaceuticals, and Apotex, among others. These companies have contributed significantly to the global fluconazole market, which is expected to grow due to an increase in fungal infections and strategic investments by key players. For more detailed information, you can refer to the official FDA drug label.